Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972842 | 0.86 | KDM2B (0.51) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL972843 | 0.86 | KDM2B (0.51) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL5317285 | 0.86 | MEN1 (0.52) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL3881644 | 0.74 | TSHR (0.57) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL1868663 | 0.74 | TSHR (0.57) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL21926954 | 0.74 | POLB (0.77) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL1860263 | 0.73 | POLB (0.52) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL1860261 | 0.73 | POLB (0.52) | KDM2BALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL3723522 | 0.72 | ALDH1A1 (0.61) | KDM2BALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL17919629 | 0.71 | KDM2B (1.00) | KDM2BALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | KDM2B 2547/4885ALDH1A1 784/4885MAPK1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.